PE20211198A1 - Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia - Google Patents

Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia

Info

Publication number
PE20211198A1
PE20211198A1 PE2021000497A PE2021000497A PE20211198A1 PE 20211198 A1 PE20211198 A1 PE 20211198A1 PE 2021000497 A PE2021000497 A PE 2021000497A PE 2021000497 A PE2021000497 A PE 2021000497A PE 20211198 A1 PE20211198 A1 PE 20211198A1
Authority
PE
Peru
Prior art keywords
vomiting
formulations
methods
induced nausea
treat chemotherapy
Prior art date
Application number
PE2021000497A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of PE20211198A1 publication Critical patent/PE20211198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2021000497A 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia PE20211198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
PE20211198A1 true PE20211198A1 (es) 2021-07-01

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000497A PE20211198A1 (es) 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia

Country Status (12)

Country Link
US (1) US20200113847A1 (enExample)
EP (1) EP3863614A1 (enExample)
JP (1) JP2022502471A (enExample)
KR (1) KR20210116432A (enExample)
AU (1) AU2019357608A1 (enExample)
BR (1) BR112021006858A2 (enExample)
CA (1) CA3115985A1 (enExample)
CL (1) CL2021000882A1 (enExample)
CO (1) CO2021005797A2 (enExample)
MX (1) MX2021004138A (enExample)
PE (1) PE20211198A1 (enExample)
WO (1) WO2020077103A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS
JP7883957B2 (ja) 2020-05-18 2026-07-02 マックス バイオロジー カンパニー リミテッド 脂質ポリマー組成物及び使用方法
AU2021347760B2 (en) * 2020-09-24 2024-07-25 Nicoventures Trading Limited Formulation
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2016129536A (ru) * 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
AU2017334283A1 (en) * 2016-09-27 2019-04-04 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) * 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
WO2019100007A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
WO2019165387A1 (en) * 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
CA3107014A1 (en) * 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions

Also Published As

Publication number Publication date
KR20210116432A (ko) 2021-09-27
MX2021004138A (es) 2021-08-05
WO2020077103A1 (en) 2020-04-16
US20200113847A1 (en) 2020-04-16
AU2019357608A1 (en) 2021-05-27
JP2022502471A (ja) 2022-01-11
CO2021005797A2 (es) 2021-05-20
BR112021006858A2 (pt) 2021-07-13
CA3115985A1 (en) 2020-04-16
EP3863614A1 (en) 2021-08-18
CL2021000882A1 (es) 2021-08-27

Similar Documents

Publication Publication Date Title
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2026002647A (es) Composiciones y metodos de uso que comprenden sustancias con acciones de plasticidad neural administradas a dosificaciones y formulaciones no psicodelicas / psicotomimeticas
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2023005140A (es) Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2020012041A (es) Formulacion farmaceutica.
GT201400111A (es) Triazolopiridinas sustituidas
MX385265B (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
MX2019010598A (es) Composicion farmaceutica que comprende selexipag.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
MX2024000140A (es) Composición consumible por vía oral con extracto de plantas.